http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2012108444-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2012-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2012108444-A1 |
| titleOfInvention | Cardiomyopathy-specific pluripotent stem cells and uses thereof |
| abstract | The present invention includes the following steps: (1) a step of bringing a test substance into contact with a pluripotent stem cell-derived cardiomyocyte or tissue having a lamin A / C gene abnormality; and (2) the myocardium as compared with the case where the test substance is not contacted. Preventing cardiomyopathy by using a test substance that changes the characteristics of normal cardiomyocytes or tissues expressed by cells or tissues so that they are close to those of normal cardiomyocytes, or prevents or delays the expression of these different characteristics And / or a method for screening a prophylactic and / or therapeutic agent for cardiomyopathy, comprising the step of selecting as a candidate substance for the therapeutic agent. |
| priorityDate | 2011-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 550.